Bulletin of the World Health Organization

Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries

Martin WG Brinkhof, François Dabis, Landon Myer, David R Bangsberg, Andrew Boulle, Denis Nash, Mauro Schechter, Christian Laurent, Olivia Keiser, Margaret May, Eduardo Sprinz, Matthias Egger, Xavier Anglaret, for the ART-LINC of IeDEA collaboration

Volume 86, Number 7, July 2008, 559-567

Table 2. Baseline characteristics of the 5491 patients starting ART who were included in the data analysis

Characteristics	Number of patients
Characteristics	(n)	(%)
Age (years)
16–29	1312	24
30–39	2491	45
40–49	1232	23
≥ 50	456	8
Median	35	30–41^a
Sex
Female	2519	46
Male	2972	54
Baseline CD4-cell count (cells/µl)
≤ 25	810	20^b
25–49	482	12^b
50–99	680	17^b
100–199	1001	24^b
200–349	767	19^b
≥ 350	347	8^b
Median	105	35–210^a
Not measured	1404	26
Clinical stage
CDC stage A/B, WHO stage I/II	760	14
CDC stage C, WHO stage III/IV	1727	31
Not recorded	3004	55
Initial ART regimen
NNRTI-based	4031	73
PI-based	988	18
Unknown or other combination	472	9
Year of starting ART
≤ 2000	1463	27
2001–2002	2432	44
2003–2004	1596	29

ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.^a Value is the interquartile range.^b Percentage of the 4087 patients whose CD4-cell count was available.

Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries

Martin WG Brinkhof, François Dabis, Landon Myer, David R Bangsberg, Andrew Boulle, Denis Nash, Mauro Schechter, Christian Laurent, Olivia Keiser, Margaret May, Eduardo Sprinz, Matthias Egger, Xavier Anglaret, for the ART-LINC of IeDEA collaboration

Table 2. Baseline characteristics of the 5491 patients starting ART who were included in the data analysis

Corporate links